Literature DB >> 10598819

SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients.

L Yin1, V Ferrand, M F Lavoué, D Hayoz, N Philippe, G Souillet, M Seri, R Giacchino, E Castagnola, S Hodgson, B S Sylla, G Romeo.   

Abstract

X-linked lymphoproliferative disease (XLP) is a rare inherited immunodeficiency to Epstein-Barr virus (EBV). The gene responsible for XLP has recently been identified as the four-exon SH2D1A gene encoding a 128-amino-acid protein that contains an SH2-domain. Functional studies indicate the SH2D1A protein acts as a regulator of at least two signal transduction pathways initiated by the cell surface molecules SLAM and 2B4, respectively, and possibly related to the host immune response to EBV infection. We have carried out a systematic mutation study of the SH2D1A gene in our series of 19 typical and 8 atypical XLP patients by polymerase chain reaction (PCR), reverse transcription/PCR, and sequencing, and have reconstructed the haplotypes of the patients. Four out of the 13 mutations detected are previously unreported. The identification of SH2D1A mutations in carriers from all three XLP families screened and the detection of mutations in two out of eight atypical patients indicates the usefulness of a DNA-based diagnosis for XLP disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598819     DOI: 10.1007/s004390051137

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  8 in total

1.  Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances.

Authors:  Xin Feng; Shaofei Wang; Quewang Liu; Han Li; Jiamei Liu; Cheng Xu; Weifeng Yang; Yayun Shu; Weiwei Zheng; Bingxin Yu; Mingran Qi; Wenyang Zhou; Fengfeng Zhou
Journal:  J Vis Exp       Date:  2018-10-11       Impact factor: 1.355

2.  A "three-pronged" binding mechanism for the SAP/SH2D1A SH2 domain: structural basis and relevance to the XLP syndrome.

Authors:  Peter M Hwang; Chengjun Li; Massimo Morra; Jennifer Lillywhite; D Ranjith Muhandiram; Frank Gertler; Cox Terhorst; Lewis E Kay; Tony Pawson; Julie D Forman-Kay; Shun-Cheng Li
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

3.  Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant.

Authors:  Paul E Gray; Tracey A O'Brien; Mayura Wagle; Stuart G Tangye; Umaimainthan Palendira; Tony Roscioli; Sharon Choo; Rosemary Sutton; John B Ziegler; Katie Frith
Journal:  J Clin Immunol       Date:  2015-10-03       Impact factor: 8.317

4.  The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-kappa B.

Authors:  B S Sylla; K Murphy; E Cahir-McFarland; W S Lane; G Mosialos; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

5.  X-linked lymphoproliferative disease: three atypical cases.

Authors:  K Nistala; K C Gilmour; T Cranston; E G Davies; D Goldblatt; H B Gaspar; A M Jones
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

6.  Severe XLP Phenotype Caused by a Novel Intronic Mutation in the SH2D1A Gene.

Authors:  B Tóth; B Soltész; E Gyimesi; G Csorba; Á Veres; Á Lányi; G Kovács; L Maródi; M Erdős
Journal:  J Clin Immunol       Date:  2014-12-10       Impact factor: 8.317

7.  Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease--report of three cases.

Authors:  B Hügle; P Suchowerskyj; H Hellebrand; B Adler; M Borte; U Sack; U Schulte Overberg-Schmidt; N Strnad; J Otto; A Meindl; V Schuster
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

8.  Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodeficiency.

Authors:  Asghar Aghamohammadi; Hirokazu Kanegane; Mostafa Moein; Abolhasan Farhoudi; Zahra Pourpak; Masoud Movahedi; Mohammad Gharagozlou; Ali Akabar Amir Zargar; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.